Oral Session 3-11A AML: Clinical siginificance of genetic abnormalities

[OS3-11A-6] Usefulness of a NPM1 mutation detection for assessment of minimal residual disease in AML

Kenta Date¹, Atsushi Marumo¹, Marika Kuboyama¹, Kensuke Usuki², Shinichi Kako³, Hitoji Uchiyama⁴, Katsuhiro Shono⁵, Yuho Najima⁶, Saiko Kurosawa⁷, Masahiro Sakaguchi¹, Shunsuke Yui¹, Satoshi Wakita¹, Kunihito Arai¹, Tomoaki Kitano¹, Kazuhiko Kakihana⁶, Takahiro Fukuda⁷, Kazuteru Ohashi⁶, Hiroki Yamaguchi¹, Koiti Inokuchi¹ (1.Hematology, Nippon Medical School, Tokyo, Japan, 2.Hematology, NTT Medical Center Tokyo, Tokyo, Japan, 3.Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 4.Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 5.Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan, 6.Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, 7.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan)